Description of the research protocol - CHU Brugmann UVC

Home
Welcome !

We hope you enjoy your visit on the website of CHU Brugmann (Brugmann University Hospital), a member of the IRIS network and of the CHU of Brussels.
With its three complementary sites and 853 recognized beds, CHU Brugmann is one of the largest hospitals in Brussels. Its assets ? An ideal size to deploy all its activities and the best possible service, a strong social personality and a resolutely university character. Without counting an advanced technical environment and constant architectural improvements. Besides, CHU Brugmann remains one of the rare hospitals with pavilion structure in Europe.
Find us also on...
- Facebook
- Twitter
- Linkedin
- Youtube
- Instagram
Virtual hospital
Three complementary sites
Quality labels
- Baby-friendly hospital (since march 2009)
- Smoke-free hospital (since end 2006)
As a member of the Brussels public hospitals network IRIS, CHU Brugmann adheres to the patients' charter. It is certainly an additional guarantee to be well received...

Networks
- Partners and allies
Departments
Consultations
Appointments
If you can not come to your appointment, please let us know at least 24 hours in advance via Internet or via our free phone line : 0800/35.088.
Hospitalization
- Hospitalization cancellation
- Trusted person and representative of the patient
Education
- Online information brochures
Training agenda
- Congresses and symposia
- Seminars and conferences
Research
- A foundation for research
- List of ongoing clinical trials
The Brugmann Foundation is a non-profit organization created within the CHU Brugmann and mandated to develop and support scientific research and stimulate the development of new medical treatments...
Last news
On the agenda

Hospital Departments Consultations Hospitalization Education Research News Job opportunities

Description of the research protocol "PREDICTUMAB"

Predictive factors of response to olalizumab and mepolizumab in severe (allergic and eosinophilic) asthma: a multicentre, open, active-controlled, randomized trial in adult patients in Belgium (PREDICTUMAB)
Phase IV study| Status : Ongoing and recruiting

Additional details

Indication (or studied pathology) : Immuno-allergologie
Brugmann identifier : PREDICTUMAB
EudraCT identifier : 2017-002473-19
ClinicalTrials.gov identifier : NCT03476109

Resources

Involved department : Immuno-allergology
Principal investigator : Michel
Sponsor : UCL
Contact : Clinical Research Unit

This protocol was approved by the UCL St Luc ethics committee.